Sutro Biopharma (STRO) Revenue (2017 - 2026)
Sutro Biopharma (STRO) posted Revenue of $6.6 million for Q4 2025, down 31.91% sequentially from $9.7 million in Q3 2025, and down 55.43% YoY from $14.8 million in Q4 2024.
Sutro Biopharma (STRO) Revenue (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Revenue for 9 years, with the latest figure at $6.6 million in Q4 2025.
- Quarterly Revenue fell 55.43% year-over-year to $6.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $97.4 million (up 57.05% YoY) and the FY2025 annual result came in at $102.5 million, up 65.18% from the prior year.
- Revenue slipped to $6.6 million in Q4 2025 per STRO's latest filing, from $9.7 million in the prior quarter.
- Over five years, Revenue peaked at $113.7 million in Q4 2023 and troughed at $5.9 million in Q1 2022.
- A 5-year average of $22.1 million and a median of $13.8 million in 2021 frame the typical range for Revenue.
- The sharpest annual moves came in 2023 and 2024: Revenue surged 1217.44% in 2023, then slumped 86.98% in 2024.
- Over 5 years, Revenue stood at $10.7 million in 2021, then retreated by 18.98% to $8.6 million in 2022, then soared by 1217.44% to $113.7 million in 2023, then plunged by 86.98% to $14.8 million in 2024, then sank by 55.43% to $6.6 million in 2025.
- According to Business Quant data, Revenue over the past three periods registered $6.6 million, $9.7 million, and $63.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | 9.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.84 Mn |
| Dec 31, 2025 | 6.60 Mn |
| Sep 30, 2025 | 9.69 Mn |
| Jun 30, 2025 | 63.75 Mn |
| Mar 31, 2025 | 17.40 Mn |
| Dec 31, 2024 | 14.81 Mn |
| Sep 30, 2024 | 8.52 Mn |
| Jun 30, 2024 | 25.71 Mn |
| Mar 31, 2024 | 13.01 Mn |
| Dec 31, 2023 | 113.72 Mn |
| Sep 30, 2023 | 16.92 Mn |
| Jun 30, 2023 | 10.41 Mn |
| Mar 31, 2023 | 12.67 Mn |
| Dec 31, 2022 | 8.63 Mn |
| Sep 30, 2022 | 25.15 Mn |
| Jun 30, 2022 | 28.10 Mn |
| Mar 31, 2022 | 5.90 Mn |
| Dec 31, 2021 | 10.65 Mn |
| Sep 30, 2021 | 8.52 Mn |
| Jun 30, 2021 | 28.05 Mn |